<p>Arcellx, Inc.（纳斯达克代码：ACLX - 获取免费报告）内部人士 Christopher Heery 于 1 月 13 日（星期二）出售了 7,437 股该股票。股票的平均售价为 65.51 美元，总交易额为 487,197.87 美元。出售完成后，该内部人士直接持有公司 29,631 股，估值约为 1,941,126.81 美元。此次交易使其持股减少了 20.06%。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。</p>
<p>Christopher Heery 最近还进行了以下交易：</p>
<ul>
<li>在 1 月 12 日（星期一），Christopher Heery 出售了 6,131 股 Arcellx 股票。股票的平均售价为 64.15 美元，总价值为 393,303.65 美元。</li>
<li>在 11 月 17 日（星期一），Christopher Heery 出售了 340 股 Arcellx 股票。股票的平均售价为 90.00 美元，总价值为 30,600.00 美元。</li>
</ul>
<h2>Arcellx 股票表现</h2>
<p>在周二的交易中，ACLX 股票上涨了 1.88 美元，达到了 66.75 美元。该股票的交易量为 520,715 股，而其平均交易量为 817,595 股。该股票的市值为 38.6 亿美元，市盈率为-16.98，贝塔值为 0.36。公司的 50 日移动平均价格为 73.26 美元，200 日移动平均价格为 74.89 美元。Arcellx, Inc.的 1 年最低价为 47.86 美元，1 年最高价为 94.07 美元。</p>
<p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）最近在 11 月 5 日（星期三）发布了季度财报。公司报告每股收益为（0.99 美元），低于分析师一致预期的（0.96 美元）3 美分。该季度的收入为 495 万美元，而分析师预期为 1,124 万美元。Arcellx 的股本回报率为-51.13%，净利润率为-607.01%。作为一个整体，卖方分析师预测 Arcellx, Inc.在当前财年将发布每股收益-1.58 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师对该公司进行了评论。Wolfe Research 在 11 月 18 日（星期二）发布的报告中开始覆盖 Arcellx。他们对该公司给予了 “同行表现” 的评级。Guggenheim 在 11 月 24 日（星期一）的报告中重申了对 Arcellx 股票的 “买入” 评级。Cantor Fitzgerald 在 10 月 9 日（星期四）的研究报告中重申了 “中性” 评级，并设定了 88.00 美元的目标价。UBS 集团在 1 月 7 日（星期三）开始覆盖 Arcellx 股票。他们对该股票给予了 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Arcellx 股票的 “卖出（d-）” 评级。九位研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 112.22 美元。</p>
<p><strong>查看我们对 Arcellx 的最新股票分析</strong></p>
<h2>对 Arcellx 的对冲基金看法</h2>
<p>几家对冲基金和其他机构投资者最近修改了对该公司的持股。MAI Capital Management 在第三季度收购了 Arcellx 的新股份，价值约 26,000 美元。CWM LLC 在第三季度将其在 Arcellx 的持股增加了 267.0%。CWM LLC 现在拥有 345 股该公司的股票，价值 28,000 美元，此前在上个季度购买了 251 股。怀俄明州在第二季度收购了 Arcellx 的新股份，价值约 28,000 美元。Ramirez Asset Management Inc.在第三季度购买了 Arcellx 的新股份，价值约 41,000 美元。最后，PNC 金融服务集团在第二季度将其在 Arcellx 的持股增加了 183.4%。PNC 金融服务集团现在拥有 751 股该公司的股票，价值 49,000 美元，此前在该期间购买了 486 股。机构投资者和对冲基金持有该公司 96.03% 的股票。</p>
<h2>关于 Arcellx</h2>
<p>（获取免费报告）</p>
<p>Arcellx, Inc.（纳斯达克：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对肿瘤和自身免疫疾病的下一代细胞疗法。公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，使其具有可交换的模块化抗原结合域，以针对多种与疾病相关的标记。</p>
<p>公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤中处于不同临床和前临床开发阶段的全资项目。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Arcellx 更好</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>行政命令 14330：特朗普最大的一次</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUFDTFg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUQI2U3ltYm9sPUFDTFg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 Arcellx 吗？</h2>
<p>在您考虑 Arcellx 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 Arcellx 并不在名单上。</p>
<p>虽然 Arcellx 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ACLX

<p>Arcellx 的内部人士 Christopher Heery 以每股 65.51 美元的价格出售了 7,437 股，总计 487,197.87 美元，减少了 20.06% 的持股比例。他目前持有 29,631 股，价值约 194 万美元。这次出售是在之前交易之后进行的，包括以每股 64.15 美元出售的 6,131 股和以每股 90.00 美元出售的 340 股。Arcellx 的股票目前交易价格为 66.75 美元，市值为 38.6 亿美元。分析师对该股票的评级不一，普遍评级为 “适度买入”，平均目标价为 112.22 美元。机构投资者持有该公司 96.03% 的股份</p>

<p>Arcellx, Inc. (NASDAQ:ACLX - Get Free Report) insider Christopher Heery sold 7,437 shares of the stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $65.51, for a total transaction of $487,197.87. Following the completion of the sale, the insider directly owned 29,631 shares in the company, valued at approximately $1,941,126.81. The trade was a 20.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Arcellx, Inc.（纳斯达克代码：ACLX - 获取免费报告）内部人士 Christopher Heery 于 1 月 13 日（星期二）出售了 7,437 股该股票。股票的平均售价为 65.51 美元，总交易额为 487,197.87 美元。出售完成后，该内部人士直接持有公司 29,631 股，估值约为 1,941,126.81 美元。此次交易使其持股减少了 20.06%。该出售在与 SEC 的法律文件中披露，您可以通过此链接访问。</p>
</div><p>Christopher Heery also recently made the following trade(s):</p>
<div class="lb-trans"><p>Christopher Heery 最近还进行了以下交易：</p>
</div><ul>
<li>On Monday, January 12th, Christopher Heery sold 6,131 shares of Arcellx stock. The stock was sold at an average price of $64.15, for a total value of $393,303.65.</li>
<li>On Monday, November 17th, Christopher Heery sold 340 shares of Arcellx stock. The stock was sold at an average price of $90.00, for a total value of $30,600.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 12 日（星期一），Christopher Heery 出售了 6,131 股 Arcellx 股票。股票的平均售价为 64.15 美元，总价值为 393,303.65 美元。</li>
<li>在 11 月 17 日（星期一），Christopher Heery 出售了 340 股 Arcellx 股票。股票的平均售价为 90.00 美元，总价值为 30,600.00 美元。</li>
</ul>
</div><h2>Arcellx Stock Performance</h2>
<div class="lb-trans"><h2>Arcellx 股票表现</h2>
</div><p>ACLX stock traded up $1.88 during trading on Tuesday, hitting $66.75. The stock had a trading volume of 520,715 shares, compared to its average volume of 817,595. The stock has a market cap of $3.86 billion, a price-to-earnings ratio of -16.98 and a beta of 0.36. The company's 50 day moving average price is $73.26 and its two-hundred day moving average price is $74.89. Arcellx, Inc. has a 1-year low of $47.86 and a 1-year high of $94.07.</p>
<div class="lb-trans"><p>在周二的交易中，ACLX 股票上涨了 1.88 美元，达到了 66.75 美元。该股票的交易量为 520,715 股，而其平均交易量为 817,595 股。该股票的市值为 38.6 亿美元，市盈率为-16.98，贝塔值为 0.36。公司的 50 日移动平均价格为 73.26 美元，200 日移动平均价格为 74.89 美元。Arcellx, Inc.的 1 年最低价为 47.86 美元，1 年最高价为 94.07 美元。</p>
</div><p>Arcellx (NASDAQ:ACLX - Get Free Report) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.99) earnings per share for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.03). The business had revenue of $4.95 million for the quarter, compared to analysts' expectations of $11.24 million. Arcellx had a negative return on equity of 51.13% and a negative net margin of 607.01%. As a group, sell-side analysts forecast that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Arcellx（纳斯达克代码：ACLX - 获取免费报告）最近在 11 月 5 日（星期三）发布了季度财报。公司报告每股收益为（0.99 美元），低于分析师一致预期的（0.96 美元）3 美分。该季度的收入为 495 万美元，而分析师预期为 1,124 万美元。Arcellx 的股本回报率为-51.13%，净利润率为-607.01%。作为一个整体，卖方分析师预测 Arcellx, Inc.在当前财年将发布每股收益-1.58 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts have commented on the company. Wolfe Research assumed coverage on Arcellx in a report on Tuesday, November 18th. They issued a &#34;peer perform&#34; rating for the company. Guggenheim restated a &#34;buy&#34; rating on shares of Arcellx in a report on Monday, November 24th. Cantor Fitzgerald reaffirmed a &#34;neutral&#34; rating and set a $88.00 price target on shares of Arcellx in a research note on Thursday, October 9th. UBS Group began coverage on shares of Arcellx in a report on Wednesday, January 7th. They issued a &#34;buy&#34; rating on the stock. Finally, Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Arcellx in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $112.22.</p>
<div class="lb-trans"><p>几位分析师对该公司进行了评论。Wolfe Research 在 11 月 18 日（星期二）发布的报告中开始覆盖 Arcellx。他们对该公司给予了 “同行表现” 的评级。Guggenheim 在 11 月 24 日（星期一）的报告中重申了对 Arcellx 股票的 “买入” 评级。Cantor Fitzgerald 在 10 月 9 日（星期四）的研究报告中重申了 “中性” 评级，并设定了 88.00 美元的目标价。UBS 集团在 1 月 7 日（星期三）开始覆盖 Arcellx 股票。他们对该股票给予了 “买入” 评级。最后，Weiss Ratings 在 10 月 8 日（星期三）的报告中重申了对 Arcellx 股票的 “卖出（d-）” 评级。九位研究分析师对该股票给予了买入评级，两位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票的共识评级为 “适度买入”，平均目标价为 112.22 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Arcellx</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Arcellx 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Arcellx</h2>
<div class="lb-trans"><h2>对 Arcellx 的对冲基金看法</h2>
</div><p>Several hedge funds and other institutional investors have recently modified their holdings of the company. MAI Capital Management acquired a new stake in shares of Arcellx in the 3rd quarter worth about $26,000. CWM LLC grew its position in Arcellx by 267.0% in the 3rd quarter. CWM LLC now owns 345 shares of the company's stock worth $28,000 after purchasing an additional 251 shares during the last quarter. State of Wyoming acquired a new stake in shares of Arcellx in the second quarter valued at approximately $28,000. Ramirez Asset Management Inc. bought a new stake in shares of Arcellx during the third quarter valued at approximately $41,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of Arcellx by 183.4% during the second quarter. PNC Financial Services Group Inc. now owns 751 shares of the company's stock worth $49,000 after buying an additional 486 shares during the period. Institutional investors and hedge funds own 96.03% of the company's stock.</p>
<div class="lb-trans"><p>几家对冲基金和其他机构投资者最近修改了对该公司的持股。MAI Capital Management 在第三季度收购了 Arcellx 的新股份，价值约 26,000 美元。CWM LLC 在第三季度将其在 Arcellx 的持股增加了 267.0%。CWM LLC 现在拥有 345 股该公司的股票，价值 28,000 美元，此前在上个季度购买了 251 股。怀俄明州在第二季度收购了 Arcellx 的新股份，价值约 28,000 美元。Ramirez Asset Management Inc.在第三季度购买了 Arcellx 的新股份，价值约 41,000 美元。最后，PNC 金融服务集团在第二季度将其在 Arcellx 的持股增加了 183.4%。PNC 金融服务集团现在拥有 751 股该公司的股票，价值 49,000 美元，此前在该期间购买了 486 股。机构投资者和对冲基金持有该公司 96.03% 的股票。</p>
</div><h2>About Arcellx</h2>
<div class="lb-trans"><h2>关于 Arcellx</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Arcellx, Inc NASDAQ: ACLX is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation cell therapies for oncology and autoimmune diseases. The company's proprietary ARC-SparX™ platform is designed to enable precise control over cell-surface receptor activation and to improve the safety, efficacy and durability of adoptive cell therapies. Leveraging this technology, Arcellx engineers immune cells with modular antigen-binding domains that can be exchanged to target a variety of disease-associated markers.</p>
<div class="lb-trans"><p>Arcellx, Inc.（纳斯达克：ACLX）是一家临床阶段的生物制药公司，专注于发现、开发和商业化针对肿瘤和自身免疫疾病的下一代细胞疗法。公司的专有 ARC-SparX™平台旨在实现对细胞表面受体激活的精确控制，并提高采用细胞疗法的安全性、有效性和持久性。利用这一技术，Arcellx 对免疫细胞进行工程改造，使其具有可交换的模块化抗原结合域，以针对多种与疾病相关的标记。</p>
</div><p>The company's pipeline comprises multiple wholly owned programs in hematologic malignancies and solid tumors at various stages of preclinical and clinical development.</p>
<div class="lb-trans"><p>公司的产品管线包括多个在血液恶性肿瘤和实体肿瘤中处于不同临床和前临床开发阶段的全资项目。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Arcellx</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Arcellx 更好</li>
<li>Elon 将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>家族信托如何帮助保护您的财富</li>
<li>一项价值数万亿的美国 “出生权” 索赔 - 静悄悄地激活</li>
<li>行政命令 14330：特朗普最大的一次</li>
<li>自 2007 年以来首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNMWA" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ACLX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Arcellx Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 Arcellx 吗？</h2>
</div><p>Before you consider Arcellx, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 Arcellx 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcellx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买...而 Arcellx 并不在名单上。</p>
</div><p>While Arcellx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Arcellx 目前在分析师中被评为适度买入，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Arcellx（NASDAQ:ACLX）的一位内部人士出售了价值 487,197.87 美元的股票